Novel targets for the treatment of autosomal dominant polycystic kidney disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Autosomal dominant (AD) polycystic kidney disease (PKD) is the most common life-threatening hereditary disorder. There is currently no therapy that slows or prevents cyst formation and kidney enlargement in humans. An increasing number of animal studies have advanced our understanding of molecular and cellular targets of PKD. AREAS COVERED IN THE REVIEW: The purpose of this review is to summarize the molecular and cellular targets involved in cystogenesis and to update on the promising therapies that are being developed and tested based on knowledge of these molecular and cellular targets. WHAT THE READER WILL GAIN: Insight into the pathogenesis of PKD and how a better understanding of the pathogenesis of PKD has led to the development of potential therapies to inhibit cyst formation and/or growth and improve kidney function. TAKE HOME MESSAGE: The results of animal studies in PKD have led to the development of clinical trials testing potential new therapies to reduce cyst formation and/or growth. A vasopressin V2 receptor antagonist, mTOR inhibitors, blockade of the renin-angiotensin system and statins that reduce cyst formation and improve renal function in animal models of PKD are being tested in interventional studies in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells
Nauli, S. M., Alenghat, F. J., Luo, Y., Williams, E., Vassilev, P., Li, X., Elia, A. E. H., Lu, W., Brown, E. M., Quinn, S. J., et al. (2003) · Nature Genetics · doi:10.1038/ng1076 · Cited by 2,057
Davenport, J. R., Watts, A. J., Roper, V. C., Croyle, M. J., van Groen, T., Wyss, J. M., Nagy, T. R., Kesterson, R. A., & Yoder, B. K. (2007) · Current Biology · doi:10.1016/j.cub.2007.08.034 · Cited by 482 · cited 1×
“Inactivation of ciliogenic genes (Kif3a) in newborn mice resulted in rapid cyst development, while inactivation of ciliogenic genes at postnatal day 10 or later resulted in a much slower rate of cyst formation [6].”
BackgroundTreatment of polycystic kidney disease with a novel tyrosine kinase inhibitor
Sweeney, W. E., Chen, Y., Nakanishi, K., Frost, P., & Avner, E. D. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00829.x · Cited by 219
Cited by
Emerging role of autophagy in kidney function, diseases and aging
Huber, T. B., Edelstein, C. L., Hartleben, B., Inoki, K., Jiang, M., Koya, D., Kume, S., Lieberthal, W., Pallet, N., Quiroga, A., et al. (2012) · Autophagy · doi:10.4161/auto.19821 · Cited by 253
Self-citationOrganoid-on-a-chip model of human ARPKD reveals mechanosensing pathomechanisms for drug discovery
Hiratsuka, K., Miyoshi, T., Kroll, K. T., Gupta, N. R., Valerius, M. T., Ferrante, T., Yamashita, M., Lewis, J. A., & Morizane, R. (2022) · Science Advances · doi:10.1126/sciadv.abq0866 · Cited by 140
Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD)
Belibi, F., Zafar, I., Ravichandran, K., Segvic, A. B., Jani, A., Ljubanovic, D. G., & Edelstein, C. L. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00348.2010 · Cited by 107
Self-citationApoptosis and autophagy in polycystic kidney disease (PKD)
Nowak, K. L., & Edelstein, C. L. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109518 · Cited by 71
“There are a multitude of signaling pathways that are either increased or decreased in PKD [3] [4] [5] [6].”
BackgroundSelf-citation
Metadata
- Authors
- Belibi, F. A., & Edelstein, C. L.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2010-02-08
- Volume
- 19
- Issue
- 3
- Pages
- 315-328
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2147825900
- Cited by
- 43
- References
- 3
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel targets for the treatment of autosomal dominant polycystic kidney disease. https://app.cochat.ai/papers/10.1517/13543781003588491
- The paper
- Belibi, F. A., & Edelstein, C. L. (2010). Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543781003588491
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.